Transnasal anticonvulsive compositions and modulated process
A novel method of vehicle modulated administration of an anticonvulsive agent to the mucous membranes of humans and animals is disclosed. The vehicle system is an aqueous pharmaceutical carrier comprising an aliphatic alcohol (10–80%) or a glycol (10–80%), and their combinations with a biological surfactant such as a bile salt or a lecithin. The pharmaceutical composition provides a means to control and promote the rate and extent of transmucosal permeation and absorption of the medicaments via a single and multiple administration. Nasal administration of the pharmaceutical preparation produces a high plasma concentration of the anticonvulsant nearly as fast as intravenous administration. Such compositions are particularly suitable for a prompt and timely medication of patients in the acute and/or emergency treatment of status epilepticus and other fever-induced seizures.
1. A pharmaceutical composition for the administration of diazepam to the nasal mucosal membranes of a mammal in a rate-controlled manner of absorption comprising diazepam and an aqueous vehicle comprising: about 60% by volume of an aliphatic alcohol having from 1 to 5 carbon atoms; about 30% by volume of a glycol selected from the group consisting of propylene glycol, polyethylene glycol 200, polyethylene glycol 300, polyethylene glycol 400, and polyethylene glycol 600; about 1% by weight of a biological surfactant selected from the group consisting of a bile salt selected from the group consisting of sodium cholate, sodium deoxycholate, sodium glycocholate, sodium taurocholate, and sodium ursodeoxycholate and a lecithin selected from the group consisting of lysophosphotidylcholine, dipalmitoylphosphotidylcholin, distearoylphosphotidylcholin, dipalmitoylphosphotidylethanolamine, and dipalmitoylphosphotidylglycerol; and about 10% by volume of water.
2. A pharmaceutical composition for the administration of clonazepan to the nasal mucosal membranes of a mammal in a rate-controlled manner of absorption comprising clonazepam and an aqueous vehicle comprising: about 30% by volume of an aliphatic alcohol having from 1 to 5 carbon atoms; about 60% by volume of a glycol selected from the group consisting of propylene glycol, polyethylene glycol 200, polyethylene glycol 300, polyethylene glycol 400, and polyethylene glycol 600; about 1% by weight of a biological suffactant selected from the group consisting of a bile salt selected from the group consisting of sodium cholate, sodium deoxycholate, sodium glycocholate, sodium taurocholate, and sodium ursodeoxycholate and a lecithin selected from the group consisting of lysophosphotidylcholine, dipalmitoylphosphotidylcholin, distearoylphosphotidylcholin, dipalmitoylphosphotidylethanolamine, and dipalmitoylphosphotidylglycerol; and about 10% by volume of water.
3. A pharmaceutical composition for the administration of (S)-2-carbamoyloxy-1-o-chlorophenylethanol to the nasal mucosal membranes of a mammal in a rate-controlled manner of absorption comprising (S)-2-carbamoyloxy-1-o-chiorophenylethanol and an aqueous vehicle comprising: about 30% by volume of an aliphatic alcohol having from 1 to 5 carbon atoms; about 60% by volume of a glycol selected from the group consisting of propylene glycol, polyethylene glycol 200, polyethylene glycol 300, polyethylene glycol 400, and polyethylene glycol 600; about 1% by weight of a biological surfactant selected from the group consisting of a bile salt selected from the group consisting of sodium cholate, sodium deoxycholate, sodium glycocholate, sodium taurocholate, and sodium ursodeoxycholate and a lecithin selected from the group consisting of lysophosphotidylcholine, dipalmitoylphosphotidylcholin, distearoylphosphotidylcholin, dipalmitoylphosphotidylethanolamine, and dipalmitoylphosphotidylglycerol; and about 10% by volume of water.